



# AETERNA ZENTARIS INC.

## FORM 6-K

(Report Of Foreign Issuer)

Filed 08/03/22 for the Period Ending 08/03/22

Address C/O NORTON ROSE FULBRIGHT CANADA LLP, TORONTO,  
A6, M5K 1E7

Telephone (727) 384-2323

CIK 0001113423

Symbol AEZS

SIC Code 2834 - Pharmaceutical Preparations

Fiscal Year 12/31

Powered by **barchart**

<https://www.barchart.com/solutions>

© Copyright 2022, Barchart.com, Inc. All Rights Reserved.

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934**

For the month of August 2022

Commission File Number: **001-38064**

**Aeterna Zentaris Inc.**

(Translation of registrant's name into English)

**c/o Norton Rose Fulbright Canada, LLP, 222 Bay Street, Suite 3000, PO Box 53, Toronto ON M5K 1E7**  
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.  
Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):



Exhibits 99.1 and 99.2, included with this report on Form 6-K are hereby incorporated by reference into the Registrant's Registration Statements on Forms S-8 (No. 333-224737, No. 333-210561 and No. 333-200834), Forms F-3 (No.333-232935 and No. 333-254680) and Forms F-1 (No.333-239264, No. 333-248561 and No. 333-239019) and shall be deemed to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

**DOCUMENTS INDEX**

<b>Exhibit</b>	<b>Description</b>
99.1	<a href="#">Aeterna Zentaris' Condensed Interim Consolidated Financial Statements - Second Quarter 2022 (Q2)</a>
99.2	<a href="#">Aeterna Zentaris' Management's Discussion and Analysis of Financial Condition and Results of Operations - Second Quarter 2022 (Q2)</a>
99.3	<a href="#">Certification of the Chief Executive Officer pursuant to National Instrument 52-109</a>
99.4	<a href="#">Certification of the Principal Financial Officer pursuant to National Instrument 52-109</a>

(2)



**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**AETERNA ZENTARIS INC.**

Date: August 3, 2022

By: /s/ Klaus Paulini

Klaus Paulini  
President and Chief Executive Officer

(3)